Title,ID
"A combination therapy of bortezomib, CXCR4 inhibitor, and checkpoint inhibitor is effective in cholangiocarcinoma <i>in vivo</i>.",PMC9950944
Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96.,PMC9495994
Leptin Augments Antitumor Immunity in Obesity by Repolarizing Tumor-Associated Macrophages.,PMC9095767
Anti-tumor effects of anti-programmed cell death-1 antibody treatment are attenuated in streptozotocin-induced diabetic mice.,PMC10097709
Evaluation of cancer immunotherapy using mini-tumor chips.,PMC9131272
Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor.,PMC8376001
Microbiota-dependent expression of CTLA-4 by innate lymphoid cells restrains IFNγ dependent colitis,10.21203/rs.3.rs-2729018/v1
Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy.,PMC9374377
Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy.,PMC10102850
Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers.,PMC9564179
Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. ,PMC8391891
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.,PMC10115650
Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody.,PMC10068443
"Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors.",PMC9510518
Targeting GPC3<sup>high</sup> cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer.,PMC10088929
Inulin prebiotic reinforces host cancer immunosurveillance <i>via</i> ɣδ T cell activation.,PMC9981629
Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy.,PMC9627263
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression.,PMC9379514
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.,PMC10083881
Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.,PMC9631798
"Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response.",PMC8674339
Solid stress impairs lymphocyte infiltration into lymph-node metastases.,PMC8678215
Oncogenic drivers dictate immune control of acute myeloid leukemia.,PMC10104832
"Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER.",PMC9890135
Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma.,PMC8267546
Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model.,PMC9868147
CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer.,PMC10104818
Increased Immunogenicity of a Minimally Immunogenic Tumor after Cancer-Targeting Near Infrared Photoimmunotherapy. ,PMC7763141
Granzyme B PET Imaging in Response to In Situ Vaccine Therapy Combined with αPD1 in a Murine Colon Cancer Model. ,PMC8779135
A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment.,PMC9563311
Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.,PMC8193643
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.,PMC7810472
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. ,PMC8402391
Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition.,PMC9750861
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.,PMC10101660
Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies.,PMC9534946
FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.,PMC9254240
"Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR.",PMC9279289
Targeting IL-27 and/or IL-10 in Experimental Murine Visceral Leishmaniasis.,PMC7646755
Imaging Memory T-Cells Stratifies Response to Adjuvant Metformin Combined with αPD-1 Therapy.,PMC9654631
Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor.,PMC8605339
Tumor Cell-Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis.,PMC9839845
GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models.,PMC8748779
Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models.,PMC9564135
PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A-producing γδ T cells.,PMC9732671
CD27 expression on Treg cells limits immune responses against tumors.,PMC8843905
Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma.,PMC9252128
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.,PMC7028345
The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B.,PMC9908333
Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1.,PMC9273650
"Deciphering Repertoire of B16 Melanoma Reactive TCRs by Immunization, In Vitro Restimulation and Sequencing of IFNγ-Secreting T Cells. ",PMC8469664
Artificial Diets with Selective Restriction of Amino Acids and Very Low Levels of Lipids Induce Anticancer Activity in Mice with Metastatic Triple-Negative Breast Cancer.,PMC10000978
CMTR1 promotes colorectal cancer cell growth and immune evasion by transcriptionally regulating STAT3.,PMC10079662
Neoadjuvant immune checkpoint blockade triggers persistent and systemic T<sub>reg</sub> activation which blunts therapeutic efficacy against metastatic spread of breast tumors.,PMC10114978
Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy.,PMC8958467
Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection.,PMC9374577
Imaging Effector Memory T-Cells Predicts Response to PD1-Chemotherapy Combinations in Colon Cancer.,PMC9598730
Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1.,PMC9262841
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells.,PMC10110685
Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade.,PMC9489681
Elicitation of stem-like CD8<sup>+</sup> T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control.,PMC9472119
ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control.,PMC9440216
"AHCC<sup>®</sup>, a Standardized Extract of Cultured Lentinula Edodes Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer.",PMC9066372
Chemical-induced lung tumor in Tg-rasH2 mice: a novel mouse tumor model to assess immune checkpoint inhibitors combined with a chemotherapy drug.,PMC9647217
Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer,PMC10136622
Therapeutic KRAS<sup>G12C</sup> inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.,PMC9299537
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy.,PMC7971263
Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy.,PMC9768337
BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC.,PMC9066214
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.,PMC6190749
An oral cancer vaccine using a <i>Bifidobacterium</i> vector suppresses tumor growth in a syngeneic mouse bladder cancer model.,PMC8449024
Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment.,PMC7658578
EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer.,PMC9406398
CaCO<sub>3</sub> powder-mediated biomineralization of antigen nanosponges synergize with PD-1 blockade to potentiate anti-tumor immunity.,PMC10080855
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens.,PMC8363284
VRK2 inhibition synergizes with PD-1 blockade to improve T cell responses.,PMC9310435
Fat mass and obesity-associated protein regulates arecoline-exposed oral cancer immune response through programmed cell death-ligand 1.,PMC9459271
Expansion of circulating stem-like CD8<sup>+</sup> T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice.,PMC10097749
Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity.,PMC9090262
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control.,PMC9835951
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.,PMC7900644
"Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone.",PMC9818024
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. ,PMC7103801
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity.,PMC10015882
A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression.,PMC9532374
"IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.",PMC10103717
Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity.,PMC10110722
Obesity results in adipose tissue T cell exhaustion. ,PMC8119198
Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.,PMC6694548
Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade.,PMC9723960
<i>In vivo</i>CRISPR screen identifies KRAS-induced COX-2 as a driver of immune evasion and immunotherapy resistance in lung cancer,10.1101/2023.04.13.536740
Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework.,PMC9760747
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors.,PMC6136850
"<i>CARD11</i> gain-of-function mutation drives cell-autonomous accumulation of PD-1<sup>+</sup> ICOS<sup>high</sup> activated T cells, T-follicular, T-regulatory and T-follicular regulatory cells.",PMC10028194
2B4 but not PD-1 blockade improves mortality in septic animals with preexisting malignancy. ,PMC6948854
Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes.,PMC9939221
Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer.,PMC10033906
Non-synergy of PD-1 blockade with T-cell therapy in solid tumors.,PMC9260838
PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease.,PMC9491709
The Siglec-sialic acid-axis is a target for innate immunotherapy of glioblastoma,10.1101/2022.11.07.515406
Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.,PMC9594625
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota.,PMC9394387
Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail.,PMC8209580
Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy. ,PMC8750027
Perfluorocarbon nanodrug induced oxygen self-enriching sonodynamic therapy improves cancer immunotherapy after insufficient radiofrequency ablation.,PMC10083362
Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.,PMC8112465
The Programmed Death-1 Signaling Axis Modulates Inflammation and LV Structure/Function in a Stress-Induced Cardiomyopathy Model.,PMC9849278
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.,PMC6822709
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma.,PMC9245557
Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model.,PMC8978397
Cargo-free immunomodulatory nanoparticles combined with anti-PD-1 antibody for treating metastatic breast cancer.,PMC7870582
Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice.,PMC6989506
Effect of M2-like macrophages of the injured-kidney cortex on kidney cancer progression.,PMC9722672
HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer.,PMC8899586
Targeting metabotropic glutamate receptor 4 for cancer immunotherapy.,PMC8664261
A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies.,PMC9451140
Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. ,PMC8749958
Adjunctive Probiotic <i>Lactobacillus rhamnosus</i> Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy <i>via</i> Restoring Antibiotic-Disrupted Gut Microbiota.,PMC8712698
Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET.,PMC9815495
Pericyte stem cells induce Ly6G<sup>+</sup> cell accumulation and immunotherapy resistance in pancreatic cancer.,PMC10074138
A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer.,PMC8403083
Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide.,PMC9325142
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. ,PMC8323468
Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model.,PMC9813181
The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer.,PMC9925043
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.,PMC7613674
Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. ,PMC8377700
A Combination of Cowpea Mosaic Virus and Immune Checkpoint Therapy Synergistically Improves Therapeutic Efficacy in Three Tumor Models. ,PMC8340625
Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.,PMC7483306
Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy.,PMC8671507
Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.,PMC5646836
ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts.,PMC8990435
Vinorelbine and Intermittent Cyclophosphamide Sensitize an Aggressive Myc-Driven B-Cell Lymphoma to Anti-PD-1 by an Immunological Memory Effective against Tumor Re-Challenge.,PMC10095342
"Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.",PMC8921579
Midostaurin Modulates Tumor Microenvironment and Enhances Efficacy of Anti-PD-1 against Colon Cancer.,PMC9563721
The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.,PMC10027707
Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.,PMC7558370
iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy.,PMC7890373
"Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in ""Cold"" Melanoma.",PMC9177805
Live Biotherapeutic <i>Lactococcus lactis</i> GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System.,PMC9455052
Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis.,PMC6297393
Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer.,PMC8119359
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.,PMC9396998
Single-cell and spatial dissection of precancerous lesions underlying the initiation process of oral squamous cell carcinoma.,PMC10011538
A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. ,PMC7478024
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.,PMC9092072
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy.,PMC9985635
Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth.,PMC7053418
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.,PMC8980021
MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation.,PMC9944270
Non-invasive Detection of Immunotherapy-Induced Adverse Events.,PMC8752648
Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment.,PMC8881216
Focal Cryo-Immunotherapy with Intratumoral IL-12 Prevents Recurrence of Large Murine Tumors,PMC10137033
Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.,PMC9844673
PD-1 Blockade During Post-partum Involution Reactivates the Anti-tumor Response and Reduces Lymphatic Vessel Density.,PMC6579890
Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer.,PMC9706583
Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.,PMC6714432
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. ,PMC8627419
Growth differentiation factor-15 slows the growth of murine prostate cancer by stimulating tumor immunity.,PMC7274405
Combined Blockade of GARP:TGF-β1 and PD-1 Increases Infiltration of T Cells and Density of Pericyte-Covered GARP<sup>+</sup> Blood Vessels in Mouse MC38 Tumors.,PMC8353334
A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma.,PMC9801655
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma.,PMC8257767
Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer. ,PMC7348725
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.,PMC9016298
Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer.,PMC7887594
Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers.,PMC8795493
"Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade.",PMC8131730
Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses.,PMC9905093
Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.,PMC8113241
Intratumor Microbiome Analysis Identifies Positive Association Between <i>Megasphaera</i> and Survival of Chinese Patients With Pancreatic Ductal Adenocarcinomas.,PMC8821101
Lacticaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites.,PMC10085781
Supramolecular Photothermal Nanomedicine Mediated Distant Tumor Inhibition via PD-1 and TIM-3 Blockage.,PMC7034522
Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I<sup>+</sup> tumors.,PMC9295797
A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection.,PMC8238246
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.,PMC8779329
PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer.,PMC8865802
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.,PMC10069584
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.,PMC6601346
MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.,PMC8431011
IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction.,PMC9703761
Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.,PMC8896050
"The Sesquiterpene Lactone-Rich Fraction of <i>Inula helenium</i> L. Enhances the Antitumor Effect of Anti-PD-1 Antibody in Colorectal Cancer: Integrative Phytochemical, Transcriptomic, and Experimental Analyses.",PMC9913754
Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.,PMC8943259
Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models.,PMC6402715
Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination.,PMC9589451
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. ,PMC8121519
Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. ,PMC8261884
Tryptophan potentiates CD8+ T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. ,PMC8323461
In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy.,PMC8825851
Therapeutic potential of <i>Clostridium butyricum</i> anticancer effects in colorectal cancer.,PMC10038047
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.,PMC8790872
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes.,PMC6868712
Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis.,PMC7856901
Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation.,PMC9621195
Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. ,PMC8534053
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.,PMC8810301
Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression. ,PMC7694978
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.,PMC9562723
PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration.,PMC9023578
Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel.,PMC8595497
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. ,PMC8320259
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.,PMC9853267
Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.,PMC8961902
Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzyme.,PMC9717613
Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.,PMC8237708
"DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects.",PMC9922899
DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.,PMC8578994
Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.,PMC8776246
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.,PMC5723438
Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy.,PMC9216510
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer.,PMC7925581
Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV. ,PMC8541339
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. ,PMC7934884
Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models.,PMC10065084
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.,PMC6542114
AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. ,PMC8329870
A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment.,PMC6286542
Therapeutic KRAS<sup>G12C</sup> inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers,10.1101/2021.10.18.464819
"Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.",PMC6078800
Combinatorial sympathetic and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockades inhibit the murine melanoma growth by targeting infiltrating T cells.,PMC8798308
Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade.,PMC7541445
"In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift.",PMC8892572
Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model.,PMC9509203
Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy.,PMC9374309
Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.,PMC7583495
Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment. ,PMC8211075
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.,PMC8959099
Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.,PMC6763724
CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect.,PMC9283527
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade.,PMC9838175
Antibody-mediated depletion of programmed death 1-positive (PD-1<sup>+</sup>) cells.,35820540
Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation.,PMC7952329
Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity. ,PMC7451475
Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma.,PMC8400712
Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model.,PMC8338806
Systemic inhibition of PTPN22 augments anticancer immunity.,PMC8409589
Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma.,PMC8312619
CD20<sup>+</sup>CD22<sup>+</sup>ADAM28<sup>+</sup> B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response.,PMC9130862
TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.,PMC6993226
Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy.,PMC9433741
Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.,PMC5617282
"Histone deacetylase inhibition promotes intratumoral CD8<sup>+</sup> T-cell responses, sensitizing murine breast tumors to anti-PD1.",PMC6879872
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.,PMC9980368
Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma.,PMC9695203
PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury. ,PMC7880414
Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy.,PMC7864871
Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer.,PMC8599839
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. ,PMC8609309
Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication. ,PMC7319776
Moderate static magnetic fields enhance antitumor CD8<sup>+</sup> T cell function by promoting mitochondrial respiration.,PMC7471296
Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma.,PMC9746623
BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8<sup>+</sup> T cells.,PMC9991923
Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy.,PMC8855709
"Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory.",PMC6791426
Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma.,PMC9064985
Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy.,PMC8263215
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.,PMC6354585
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.,PMC8137816
ZEB1 transcription factor promotes immune escape in melanoma.,PMC8921918
Thymosin α1 protects from CTLA-4 intestinal immunopathology. ,PMC7441522
Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy. ,PMC8745184
A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models.,PMC9654894
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.,PMC9631340
Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response,PMC4652564
Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy.,PMC7714509
CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas.,PMC9243005
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages. ,PMC7986673
PD-1 blockade enhances the vaccination-induced immune response in glioma. ,PMC4951098
Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. ,PMC7811803
Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy,PMC10146892
Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor.,PMC9772690
Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells.,PMC10140025
Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy. ,PMC6152940
Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma.,PMC9218293
Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models.,PMC9684407
Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.,PMC8439241
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma.,PMC9617949
"Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies.",PMC9178990
"Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.",PMC8974133
Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers.,PMC7442115
Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8<sup>+</sup> T-Cell Responses.,PMC8693074
Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer.,PMC10101955
Tumor necrosis factor receptor regulation of peripheral node addressin biosynthetic components in tumor endothelial cells.,PMC9520236
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.,PMC9546900
Efficient Anti-Tumor Immunotherapy Using Tumor Epitope-Coated Biodegradable Nanoparticles Combined With Polyinosinic-Polycytidylic Acid and an Anti-PD1 Monoclonal Antibody.,PMC9634146
Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer. ,PMC8391594
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.,PMC7806186
B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer.,PMC6911685
PD-1 expression on CD8<sup>+</sup> T cells regulates their differentiation within lung allografts and is critical for tolerance induction.,PMC5739961
Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.,PMC6844329
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.,PMC7706287
Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.,PMC6359760
Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.,PMC6547269
Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.,PMC7956114
Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer.,PMC9087086
Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. ,PMC6101707
"Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma.",PMC6492981
CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.,PMC8748230
"RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.",PMC7641792
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy <i>via</i> diminishing PD-L1 and promoting CD8<sup>+</sup> T cell-mediated ferroptosis in castration-resistant prostate cancer.,PMC8897216
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.,PMC5680273
Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients.,PMC8776860
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.,PMC6310483
Pharmacologic Activation of the G Protein-Coupled Estrogen Receptor Inhibits Pancreatic Ductal Adenocarcinoma.,PMC7578406
The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model.,PMC9681804
The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings.,PMC8959817
Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.,PMC5827952
"Single-Cell Landscape Highlights Heterogenous Microenvironment, Novel Immune Reaction Patterns, Potential Biomarkers and Unique Therapeutic Strategies of Cervical Squamous Carcinoma, Human Papillomavirus-Associated (HPVA) and Non-HPVA Adenocarcinoma.",PMC10074047
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.,PMC9126729
Quantification of the anti-murine PD-1 monoclonal antibody RMP1-14 in BALB/c mouse plasma by liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study.,31832706
"Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.",PMC4765931
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.,PMC8170529
Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes. ,PMC7098715
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.,PMC8282775
Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations.,PMC9018752
Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T<sub>reg</sub> cells.,PMC6506245
"Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV<sup>+</sup> Cancers.",PMC7485376
CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.,PMC7482823
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.,PMC7661742
A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells. ,PMC8363286
Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity.,PMC7463314
Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma.,PMC10140615
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts.,PMC7921555
Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker.,PMC8645761
CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. ,PMC7259512
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. ,PMC8256839
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.,PMC7770056
Temozolomide promotes immune escape of GBM cells via upregulating PD-L1.,PMC6610056
When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer.,PMC9007500
Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach.,PMC7934630
Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer.,PMC9090256
Common germline variants of the human APOE gene modulate melanoma progression and survival.,PMC8058866
Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression.,PMC9381102
Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy.,PMC7022165
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.,PMC5414865
Immunization with short peptide particles reveals a functional CD8<sup>+</sup> T-cell neoepitope in a murine renal carcinoma model.,PMC8647534
Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.,PMC9504159
Radiation-activated secretory proteins of <i>Scgb1a1</i><sup>+</sup> club cells increase the efficacy of immune checkpoint blockade in lung cancer.,PMC8670735
Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma.,PMC7492272
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.,PMC9479603
Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity.,PMC9512696
Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer.,PMC7520806
Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.,PMC6902401
An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. ,PMC5748605
PD-1 expression affects cytokine production by ILC2 and is influenced by peroxisome proliferator-activated receptor-γ.,PMC7016838
Immune modulation resulting from MR-guided high intensity focused ultrasound in a model of murine breast cancer.,PMC7806949
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.,PMC9613684
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy.,PMC8827285
Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells.,PMC9304406
STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.,PMC6133940
Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma.,PMC6287793
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.,PMC6796942
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity.,PMC7550718
Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.,PMC7026672
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy.,PMC9114862
Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.,PMC8206133
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.,PMC9401455
Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth.,PMC8102379
Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model.,PMC7904807
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.,PMC8776878
SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function.,PMC9199348
"AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models.",PMC6923872
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.,PMC9398179
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors.,PMC8960844
Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.,PMC8326929
Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.,PMC9397636
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. ,PMC7373332
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used.,PMC8505306
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.,PMC6272102
Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells.,PMC5665850
"Anti-PD-1 Therapy Does Not Influence Hearing Ability in the Most Sensitive Frequency Range, but Mitigates Outer Hair Cell Loss in the Basal Cochlear Region. ",PMC7555949
SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.,PMC8678351
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity.,PMC9524203
CD39<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup> T cells mediate metastatic dormancy in breast cancer.,PMC7859213
Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.,PMC10042735
m<sup>6</sup>A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.,PMC6592937
Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFκB axis. ,PMC8202116
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma.,PMC8583008
Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer.,PMC7606378
Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.,PMC6637625
Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.,PMC7195409
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.,PMC6262474
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.,PMC6556847
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.,PMC7795594
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect.,PMC9701141
Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade.,PMC7657645
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.,PMC8017821
PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment.,PMC8121797
Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade. ,PMC7453903
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent Cancer Models.,PMC10010340
Tumor-Specific CD4<sup>+</sup> T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4<sup>-</sup> T Cells.,PMC9243303
TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.,PMC6943983
Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages.,PMC7053633
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.,PMC6689178
STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer.,PMC8175605
An Immunocompetent Model of Pancreatic Cancer Resection and Recurrence.,PMC7896482
CTLA-4 blockade drives loss of T<sub>reg</sub> stability in glycolysis-low tumours.,PMC8057670
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma. ,PMC7422659
Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma.,PMC9880004
Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment. ,PMC7350271
Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.,PMC9274752
Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.,PMC6693252
Combinations of Radiotherapy with Vaccination and Immune Checkpoint Inhibition Differently Affect Primary and Abscopal Tumor Growth and the Tumor Microenvironment. ,PMC7916259
Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases.,PMC6597207
Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.,PMC7255037
Concomitant deletion of Ptpn6 and Ptpn11 in T cells fails to improve anticancer responses.,PMC9638855
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma. ,PMC8822220
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8<sup>+</sup> T cells eradicates peritoneal metastases in mouse models.,PMC9757485
A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.,PMC7519254
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses.,PMC8976792
Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice.,PMC5687305
Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis.,PMC10015073
Tumor Size Matters-Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy. ,PMC7140082
Combining activatable nanodelivery with immunotherapy in a murine breast cancer model.,PMC6660242
Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.,PMC9115109
Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death.,PMC5589518
Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells.,PMC6148788
"Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.",PMC9639568
Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.,PMC8325261
Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects. ,PMC7418776
Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations.,PMC7311370
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy. ,PMC7467529
CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma.,PMC9455608
In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. ,PMC7566437
Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.,PMC7456619
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.,PMC6392299
Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.,PMC9399904
Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.,PMC5790484
Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation.,PMC6493227
Development of Immunotherapy Combination Strategies in Cancer.,PMC8178168
Harnessing the reverse cholesterol transport pathway to favor differentiation of monocyte-derived APCs and antitumor responses.,PMC9932151
"Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.",PMC9381133
In situ genetic engineering of tumors for long-lasting and systemic immunotherapy.,PMC7049107
Highly Efficient and Versatile Plasmid-Based Gene Editing in Primary T Cells.,PMC5857648
Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.,PMC7790996
"Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.",PMC6000956
Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway.,PMC6433108
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.,PMC8330562
Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs. ,PMC7356959
Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy.,PMC8321414
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.,PMC7195420
Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses Against Hepatocellular Carcinoma. ,PMC7696968
Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer.,PMC7799360
Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.,PMC8006848
Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma.,PMC8284815
Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy.,PMC5715147
Immunomodulatory Effects by Photodynamic Treatment of Glioblastoma Cells In Vitro.,PMC9181863
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.,PMC6880482
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. ,PMC6483637
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.,PMC5209798
CD200 promotes immunosuppression in the pancreatic tumor microenvironment. ,PMC7312341
Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors.,PMC7000510
Hemolysis-associated phosphatidylserine exposure promotes polyclonal plasmablast differentiation. ,PMC8040514
High-salt diet inhibits tumour growth in mice via regulating myeloid-derived suppressor cell differentiation.,PMC7138858
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.,PMC6134794
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.,PMC6619502
Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment.,PMC8885837
Immunostimulatory TLR7 agonist-nanoparticles together with checkpoint blockade for effective cancer immunotherapy. ,PMC7904104
"Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia. ",PMC6765191
Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors.,PMC9831609
Engineered Microparticles for Treatment of Murine Brain Metastasis by Reprograming Tumor Microenvironment and Inhibiting MAPK Pathway.,PMC10015898
Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. ,PMC8256000
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4<sup>+</sup> T Cell Immunity.,PMC6954108
Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.,PMC7125038
CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor Function.,PMC6445751
Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.,PMC7801125
Host response to immune checkpoint inhibitors contributes to tumor aggressiveness. ,PMC7957134
Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy.,PMC7032014
Identification of a PD-L1+Tim-1+ iNKT subset that protects against fine particulate matter-induced airway inflammation.,PMC9746902
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.,PMC5735564
Targeted Delivery of Exosomes Armed with Anti-Cancer Therapeutics. ,PMC8782002
CD8<sup>+</sup> T-Cell Density Imaging with <sup>64</sup>Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols.,PMC6215696
Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.,PMC6619768
Metabolic reprogramming of terminally exhausted CD8<sup>+</sup> T cells by IL-10 enhances anti-tumor immunity.,PMC7610876
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. ,PMC7197026
Rational design of anti-GITR-based combination immunotherapy.,PMC7457830
Potentiating CD8<sup>+</sup> T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling.,PMC8018994
A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice.,PMC5628791
Sustained epidermal powder drug delivery via skin microchannels.,PMC5377446
Regulation of tumor growth by leukocyte-specific protein 1 in T cells. ,PMC7537340
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. ,PMC7057431
Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.,PMC8921917
DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure.,PMC7132619
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.,PMC4794351
Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model.,PMC6095935
Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen-Induced Lung Cancer and Determines the Efficacy of Immunotherapy.,PMC7878420
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.,PMC7028933
"Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.",PMC7141083
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.,PMC6372650
Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.,PMC7611091
Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade.,PMC7412675
Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response.,PMC9347971
Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.,PMC9228425
"Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.",PMC6085109
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.,PMC5873884
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.,PMC5983325
Fatty acid transport protein 2 reprograms neutrophils in cancer.,PMC6557120
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.,PMC7733907
Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity.,PMC10080670
Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.,PMC5777287
Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity.,PMC8856615
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.,PMC6501221
A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control.,PMC6791440
Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance.,PMC9663509
Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.,PMC6801091
Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma. ,PMC5877613
Imaging immunity in patients with cancer using positron emission tomography.,PMC8989882
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.,PMC5587366
Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment.,PMC10105078
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. ,PMC7931761
Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.,PMC5010476
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.,PMC7113205
Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment.,PMC7048819
Systemic Immunity Is Required for Effective Cancer Immunotherapy.,PMC5312823
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.,PMC9330544
High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity.,PMC8442882
In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response.,PMC8424660
Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition.,PMC6791428
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.,PMC4987196
Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.,PMC6209421
STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer.,PMC9599947
Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation. ,PMC6521128
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity.,PMC6160747
Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.,PMC7840658
Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma,PMC10130518
Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers.,PMC9144656
Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice.,PMC8049297
Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.,PMC9684196
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas. ,PMC7990326
Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. ,PMC6237456
Depletion of PD-1-positive cells ameliorates autoimmune disease.,PMC6452906
A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth. ,PMC7373330
TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.,PMC4767487
Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation.,PMC6037035
T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.,PMC5918896
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade.,PMC6437555
The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.,PMC5347092
"MP0250, a VEGF and HGF neutralizing DARPin<sup>®</sup> molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models.",PMC5716736
Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors.,PMC9327097
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.,PMC5384417
Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.,PMC6278902
"Increased diversity with reduced ""diversity evenness"" of tumor infiltrating T-cells for the successful cancer immunotherapy.",PMC5773695
Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro. ,PMC7177768
Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model.,PMC7358653
ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.,PMC6104973
Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice.,PMC9980712
Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor.,PMC6213322
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.,PMC7416458
Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy. ,PMC6975264
Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality. ,PMC7073779
Trypanosoma brucei triggers a broad immune response in the adipose tissue.,PMC8476018
Combination immune checkpoint blockade as an effective therapy for mesothelioma.,PMC6169578
Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.,PMC8362934
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.,PMC5716880
Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.,PMC5927534
Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.,PMC9300859
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming.,PMC7925544
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.,PMC6033351
Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.,PMC5871846
Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.,PMC4740221
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.,PMC5980384
Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma.,PMC9328186
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.,PMC5809273
Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications.,PMC7035142
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.,PMC6527276
Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer.,PMC9336524
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. ,PMC6521201
Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.,PMC5995819
"ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance.",PMC8062530
PD1 Deficiency Modifies Cardiac Immunity during Baseline Conditions and in Reperfused Acute Myocardial Infarction.,PMC9321105
"LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.",PMC8366543
An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.,PMC6279336
CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma.,PMC9006312
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.,PMC4597191
"SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.",PMC5347755
Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation.,PMC7549621
Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.,PMC8192781
Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation.,PMC7156731
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.,PMC6397686
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.,PMC8182921
"Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.",PMC6324578
Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.,PMC4822778
Radiotherapy induces responsiveness of a resistant mammary carcinoma to PD-1 blockade,PMC4288536
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.,PMC6883539
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.,PMC5457316
CD146 bound to LCK promotes T cell receptor signaling and antitumor immune responses in mice. ,PMC8553567
A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy.,PMC6003883
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. ,PMC7445339
Combining Adoptive Cell Therapy with Cytomegalovirus-Based Vaccine Is Protective against Solid Skin Tumors.,PMC5775971
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.,PMC7381364
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.,PMC5835021
Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia.,PMC5308636
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors. ,PMC8783833
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.,PMC5437702
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.,PMC6237485
Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer.,PMC9694305
Hyperbaric Oxygen Boosts PD-1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid Tumors.,PMC8336507
"Syntaxin-6, a Reliable Biomarker for Predicting the Prognosis of Patients with Cancer and the Effectiveness of Immunotherapy.",PMC9817965
Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.,PMC6293078
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.,PMC4650573
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.,PMC6994577
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer. ,PMC6025420
Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic <i>Trypanosoma cruzi</i> Infection.,PMC5949529
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. ,PMC5931128
A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.,28288993
Imaging Kv1.3 Expressing Memory T Cells as a Marker of Immunotherapy Response. ,PMC8909107
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.,PMC5067905
Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies.,PMC8320893
"Generation of highly activated, antigen-specific tumor-infiltrating CD8<sup>+</sup> T cells induced by a novel T cell-targeted immunotherapy.",PMC7458631
S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor.,PMC9899614
miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.,PMC5993583
"Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens.",PMC10006227
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.,PMC5013604
Intra-Tumoral Delivery of IL-27 Using Adeno-Associated Virus Stimulates Anti-tumor Immunity and Enhances the Efficacy of Immunotherapy.,PMC7118910
Antibodies against endogenous retroviruses promote lung cancer immunotherapy.,PMC10115647
Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model.,PMC9705341
Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study.,PMC9913709
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. ,PMC5621908
Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8<sup>+</sup> T cells.,PMC5672794
Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures.,PMC6225773
A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection.,PMC3569435
Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules.,PMC6608046
"Norepinephrine inhibits CD8<sup>+</sup> T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma.",PMC10050078
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.,PMC6708368
Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors.,PMC9630337
Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.,PMC5503599
"Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.",PMC5329017
"Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.",PMC6529991
CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy.,PMC7851488
Replicating viral vector platform exploits alarmin signals for potent CD8<sup>+</sup> T cell-mediated tumour immunotherapy.,PMC5458557
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.,PMC6842624
Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin. ,PMC8286790
Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens.,PMC4625129
Infection-induced plasmablasts are a nutrient sink that impairs humoral immunity to malaria.,PMC7316608
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.,PMC4079842
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.,PMC6597257
Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models.,PMC9377732
Correlates of Follicular Helper Bias in the CD4 T Cell Response to a Retroviral Antigen.,PMC6008654
The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer.,PMC5889285
PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8<sup>+</sup> T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination.,PMC5731479
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy.,PMC9662195
Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms.,PMC6726554
Nanocomplex-based <i>TP53</i> gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms.,PMC5993490
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. ,PMC5794340
Mouse-Derived Isograft (MDI) In Vivo Tumor Models I. Spontaneous sMDI Models: Characterization and Cancer Therapeutic Approaches. ,PMC6406567
"A novel built-in adjuvant metallothionein-3 aids protein antigens to induce rapid, robust, and durable immune responses.",PMC9680554
EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.,PMC5593700
Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.,PMC9823149
Reprogramming the immunological microenvironment through radiation and targeting Axl.,PMC5196438
"A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella.",PMC9065466
Induction of DNMT3B by PGE2 and IL6 at Distant Metastatic Sites Promotes Epigenetic Modification and Breast Cancer Colonization.,PMC7299749
CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. ,PMC6328023
PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.,PMC4747210
Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer.,PMC8595997
CD301b<sup>+</sup> dendritic cells suppress T follicular helper cells and antibody responses to protein antigens.,PMC5033605
Targeting CD73 in the tumor microenvironment with MEDI9447.,PMC5007986
Single-Cell Analyses of a Novel Mouse Urothelial Carcinoma Model Reveal a Role of Tumor-Associated Macrophages in Response to Anti-PD-1 Therapy.,PMC9139541
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.,PMC5741628
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.,PMC7486376
B cell-Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer.,PMC7056532
Lack of MHC class II molecules favors CD8<sup>+</sup> T-cell infiltration into tumors associated with an increased control of tumor growth.,PMC5790350
Coimmunomodulation of tumor and tumor-draining lymph nodes during in situ vaccination promotes antitumor immunity.,PMC9309043
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.,PMC9762783
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.,PMC5980491
Role of the PD-1/PD-L1 Pathway in Experimental <i>Trypanosoma cruzi</i> Infection and Potential Therapeutic Options.,PMC9260015
Active recruitment of anti-PD-1-conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy.,PMC10058243
Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5<sup>-/-</sup> mice.,PMC6445090
Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors.,PMC8899519
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1<sup>-</sup>CD8<sup>+</sup> Tumor-Infiltrating T Cells.,PMC6336113
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.,PMC5464463
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.,PMC5241182
Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model.,PMC9896027
KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression.,PMC7668036
Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation.,PMC9900174
Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.,PMC5363727
MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma.,PMC8924240
Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses.,PMC7790498
Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists. ,PMC7558881
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.,PMC5791558
Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1. ,PMC8583214
"INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses.",PMC9853254
A LAT-Based Signaling Complex in the Immunological Synapse as Determined with Live Cell Imaging Is Less Stable in T Cells with Regulatory Capability. ,PMC7921939
Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.,PMC5913311
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.,PMC5422104
Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma.,PMC7825641
Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF<sup>V600E</sup> melanoma.,PMC4839378
Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma.,PMC9944647
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.,PMC9963691
"Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.",PMC10024396
CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.,PMC5927540
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.,PMC6562565
Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner.,PMC9277914
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.,PMC5568814
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.,PMC5510474
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).,PMC8492343
Programmed death-1 controls T cell survival by regulating oxidative metabolism.,PMC4562423
"SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.",PMC4938367
Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review.,PMC9046545
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.,PMC8057655
A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities.,PMC8819036
Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. ,PMC8156558
Chromogranin A Deficiency Confers Protection From Autoimmune Diabetes via Multiple Mechanisms.,PMC8660984
Intratumoral delivery of TransCon<sup>™</sup> TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction.,PMC9484246
Programmed cell death-1 receptor mediated regulation of Tbet<sup>+</sup> NK1.1<sup>−</sup> Innate Lymphoid Cells within the Tumor Microenvironment,10.1101/2022.09.21.507469
Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. ,PMC7761875
LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs.,PMC8986222
Tailoring biomaterials and applications targeting tumor-associated macrophages in cancers.,PMC9691967
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.,PMC7514066
New Insights into the Role of PD-1 and Its Ligands in Allergic Disease. ,PMC8584538
Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review.,PMC5593644
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.,PMC6668692
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. ,PMC5928864
Insights into CD8 T Cell Activation and Exhaustion from a Mouse Gammaherpesvirus Model.,PMC7185348
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.,PMC7674951
Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response.,PMC8590766
Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression.,PMC9407017
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.,PMC6542636
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.,PMC5135381
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.,PMC4182950
Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. ,PMC5559204
The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.,PMC4048893
A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors.,PMC9037414
AZD4625 is a Potent and Selective Inhibitor of KRASG12C.,PMC9538594
PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype.,PMC9523278
Tim-3 expression and its role in hepatocellular carcinoma.,PMC6182863
Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.,PMC3868659
Endogenous Glucocorticoid Signaling Regulates CD8<sup>+</sup> T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment.,PMC7682805
The identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma.,PMC7599220
Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors.,PMC6030475
Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.,PMC7612191
Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells.,PMC4530202
Agonistic anti-CD40 enhances the CD8+ T cell response during vesicular stomatitis virus infection.,PMC4148391
"Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.",PMC8987763
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. ,PMC6975266
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.,PMC4390506
IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma.,PMC8042242
Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti-PD-1 Treatment Efficacy in Urothelial Carcinoma. ,PMC7825793
"CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.",PMC7921591
Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer.,PMC9642964
UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model.,PMC5820096
Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer.,PMC8410722
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy.,PMC6037030
A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment.,PMC8319313
An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.,PMC5601012
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.,PMC5788037
Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo.,PMC3387068
Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming.,PMC8655819
Costimulator B7-DC attenuates strong Th2 responses induced by Nippostrongylus brasiliensis.,PMC4862405
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity.,PMC4801446
Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity.,PMC5893394
Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering.,PMC6713500
"Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis.",PMC8246030
Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. ,PMC8005156
TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.,PMC8987798
Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells.,PMC8137905
Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response.,PMC9592600
Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver.,PMC2947571
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.,PMC9373855
Anti-PD-1 Antibody Administration following Hip Fracture Surgery Reverses Immune Dysfunction and Decreases Susceptibility to Infection.,PMC6470458
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.,PMC10010332
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.,PMC9720541
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.,PMC5939041
Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.,PMC6387472
Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents. ,PMC7370297
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.,PMC8185359
Tumor-Secreted GRP78 Promotes the Establishment of a Pre-metastatic Niche in the Liver Microenvironment.,PMC7550426
Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.,PMC8116573
Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting.,PMC8639654
Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism.,PMC4851431
Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells.,PMC6138242
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance.,PMC9755965
PD-1/PD-L1 pathway: current researches in cancer.,PMC7136921
Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy. ,PMC8237741
The PD-1 Regulatory Axis Inhibits T Cell-Independent B Cell Memory Generation and Reactivation.,PMC8492549
Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling.,PMC8237104
PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine.,PMC6277664
NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer.,PMC8040227
CD4+ T cell hyporesponsiveness after repeated exposure to Schistosoma mansoni larvae is dependent upon interleukin-10.,PMC4363412
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer. ,PMC6627630
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy.,PMC9330341
Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response. ,PMC7254099
Interleukin-27 Gene Therapy Prevents the Development of Autoimmune Encephalomyelitis but Fails to Attenuate Established Inflammation due to the Expansion of CD11b<sup>+</sup>Gr-1<sup>+</sup> Myeloid Cells.,PMC5928207
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.,PMC8603290
Programmed death ligand-1 induction restrains the cytotoxic T lymphocyte response against microglia.,PMC8549117
Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. ,PMC7455061
Granzyme B PET Imaging of Immune Checkpoint Inhibitor Combinations in Colon Cancer Phenotypes.,PMC7497445
"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer.",PMC8565817
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.,PMC7917457
AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia.,PMC7611942
Non-canonical PD-1 signaling in cancer and its potential implications in clinic. ,PMC7888367
CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. ,PMC7482493
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.,PMC7613740
"The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.",PMC6697571
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.,PMC6891207
Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity. ,PMC7761623
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.,PMC4955062
"Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens.",PMC8355054
Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment.,PMC8987059
Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer. ,PMC7394300
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.,PMC6159991
One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer.,PMC9311321
Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade.,PMC8783073
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.,PMC4522159
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1<sup>+</sup>CD38<sup>hi</sup> cells and anti-PD-1 resistance.,PMC7472661
Effects of a Unique Combination of the Whole-Body Low Dose Radiotherapy with Inactivation of Two Immune Checkpoints and/or a Heat Shock Protein on the Transplantable Lung Cancer in Mice. ,PMC8231142
Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model.,PMC5329671
"Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.",PMC5228566
DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance.,PMC7384226
Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.,PMC6939620
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.,PMC7479950
Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. ,PMC7698460
A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells.,PMC8603209
A RORγt<sup>+</sup> cell instructs gut microbiota-specific T<sub>reg</sub> cell differentiation.,PMC9908423
"Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation.",PMC8732307
PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism.,PMC4339454
Amino acids and RagD potentiate mTORC1 activation in CD8+ T cells to confer antitumor immunity. ,PMC8061841
BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy.,PMC9164498
Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. ,PMC8261891
A novel mouse model for checkpoint inhibitor-induced adverse events.,PMC7877613
Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.,PMC6279422
Induction of Therapeutic Protection in an HPV16-Associated Mouse Tumor Model Through Targeting the Human Papillomavirus-16 E5 Protein to Dendritic Cells.,PMC7947241
Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.,PMC8929386
Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer.,PMC9767871
Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.,PMC7846853
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.,PMC7002203
Functional Change of Effector Tumor-Infiltrating CCR5+CD38+HLA-DR+CD8+ T Cells in Glioma Microenvironment.,PMC6794477
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.,PMC8897596
Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma.,PMC5790525
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.,PMC6361951
Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection.,PMC3597521
JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy. ,PMC8404475
Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.,PMC7655953
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. ,PMC7944996
Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma.,PMC4440042
AIEgen-coupled upconversion nanoparticles eradicate solid tumors through dual-mode ROS activation.,PMC7319755
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.,PMC8110980
Advances in Oligonucleotide Aptamers for NSCLC Targeting. ,PMC7504093
Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.,PMC8851374
Aptamer Therapeutics in Cancer: Current and Future. ,PMC5876655
"The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.",PMC6504180
Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells. ,PMC7254126
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.,PMC7149500
The role of NK cells and CD39 in the immunological control of tumor metastases.,PMC6492967
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.,PMC7777391
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis.,PMC3620347
Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity.,PMC7443308
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.,PMC3084100
Batf3<sup>+</sup> DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.,PMC6343771
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.,PMC7611230
Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. ,PMC7371367
Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. ,PMC7887378
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. ,PMC8869718
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.,PMC5682289
Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy.,PMC6581740
Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells.,PMC7671443
Suppressive IL-17A<sup>+</sup>Foxp3<sup>+</sup> and ex-Th17 IL-17A<sup>neg</sup>Foxp3<sup>+</sup> T<sub>reg</sub> cells are a source of tumour-associated T<sub>reg</sub> cells.,PMC5355894
Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.,PMC5523579
Human-correlated genetic HCC models identify combination therapy for precision medicine,10.21203/rs.3.rs-1638504/v1
Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.,PMC6894345
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.,PMC5785245
Tim-3 and PD-1 regulate CD8<sup>+</sup> T cell function to maintain early pregnancy in mice.,PMC5481631
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.,PMC6274590
Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.,PMC6415684
Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma. ,PMC8424468
Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.,PMC6492961
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.,PMC5547907
Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy.,PMC5821496
Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. ,PMC7057481
Tumor location impacts immune response in mouse models of colon cancer.,PMC5589620
An antigen-encapsulating nanoparticle platform for T<sub>H</sub>1/17 immune tolerance therapy.,PMC5237397
T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect.,PMC7445289
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.,PMC8555464
Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens.,PMC3213689
Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice.,PMC7733808
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.,PMC5993506
Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.,PMC6394491
Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. ,PMC6237477
Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells.,PMC6989134
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. ,PMC5734617
Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.,PMC5889101
An intrinsic role of IL-33 in T<sub>reg</sub> cell-mediated tumor immunoevasion.,PMC7030950
Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.,PMC6571046
The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.,PMC5407496
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.,PMC6391090
A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.,PMC5669819
Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.,PMC6642145
Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa.,PMC5749661
Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes.,PMC7502486
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.,PMC5656588
Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells. ,PMC6824424
Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy.,PMC9662940
Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.,PMC5685707
Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction.,PMC3683836
Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy.,PMC6157276
Persistent STAT5 activation reprograms the epigenetic landscape in CD4+ T cells to drive polyfunctionality and antitumor immunity. ,PMC8265158
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.,PMC5036540
Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.,PMC5135645
β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8<sup>+</sup> T Cells and Undermines Checkpoint Inhibitor Therapy.,PMC5645237
Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.,PMC6192309
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.,PMC6205399
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.,PMC5830328
PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production.,PMC3605233
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.,PMC4694995
Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.,PMC6752715
Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages.,PMC4589056
Langerhans Cells Prevent Autoimmunity via Expansion of Keratinocyte Antigen-Specific Regulatory T Cells.,PMC5828466
WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.,PMC6169577
IL-21 Is Important for Induction of KLRG1+ Effector CD8 T Cells during Acute Intracellular Infection.,PMC4959448
STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFα mediated immune responses in a model of NSCLC.,PMC6324686
Compromised counterselection by FAS creates an aggressive subtype of germinal center lymphoma. ,PMC7694576
Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.,PMC5414887
Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.,PMC5380540
LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells.,PMC8386750
The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression.,PMC6225783
Lin<sup>-</sup>CCR2<sup>+</sup> hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade.,PMC6192988
"The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. ",PMC8508450
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.,PMC5564579
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8<sup>+</sup> T cell trafficking.,PMC5816160
T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis.,PMC3155998
Mutations in <i>BRCA1</i> and <i>BRCA2</i> differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.,PMC8023400
TNF-α Coordinates Hematopoietic Stem Cell Survival and Myeloid Regeneration.,PMC6733032
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.,PMC5430862
"Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. ",PMC6521062
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.,PMC5353935
The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.,PMC4987735
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.,PMC5391624
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.,PMC4817928
NK cell heparanase controls tumor invasion and immune surveillance.,PMC5490772
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.,PMC4979067
Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance.,PMC3368550
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.,PMC5119632
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.,PMC5974350
MHC-II neoantigens shape tumour immunity and response to immunotherapy.,PMC6858572
Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors.,PMC5467990
A20 Curtails Primary but Augments Secondary CD8<sup>+</sup> T Cell Responses in Intracellular Bacterial Infection.,PMC5177869
PD-1 and Tim-3 pathways are associated with regulatory CD8+ T-cell function in decidua and maintenance of normal pregnancy.,PMC4669692
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.,PMC3851914
PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity.,PMC4433434
Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma.,PMC3518504
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. ,PMC7549316
Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.,PMC4996670
L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy.,PMC6582763
Defective transcription elongation in a subset of cancers confers immunotherapy resistance.,PMC6199328
PD-1 modulates steady-state and infection-induced IL-10 production in vivo.,PMC3955717
A Novel Model of Asymptomatic Plasmodium Parasitemia That Recapitulates Elements of the Human Immune Response to Chronic Infection.,PMC5008831
Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy.,PMC4839335
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.,PMC5924916
The mTORC1-4E-BP-eIF4E axis controls de novo Bcl6 protein synthesis in T cells and systemic autoimmunity.,PMC5557982
Type I Interferon Receptor Deficiency in Dendritic Cells Facilitates Systemic Murine Norovirus Persistence Despite Enhanced Adaptive Immunity.,PMC4915689
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.,PMC4864363
Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma.,PMC2951873
High-avidity T cells are preferentially tolerized in the tumor microenvironment.,PMC4222512
Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.,PMC6400540
Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.,PMC4351071
The Polyunsaturated Fatty Acids Arachidonic Acid and Docosahexaenoic Acid Induce Mouse Dendritic Cells Maturation but Reduce T-Cell Responses In Vitro.,PMC4664484
Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.,PMC3956448
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.,PMC3978796
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.,PMC5824730
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.,PMC3476734
Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function.,PMC3412026
Tolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine Splenocytes.,PMC4517781
PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft.,PMC2887673
Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy.,PMC4297948
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.,PMC6980372
"Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction.",PMC3643762
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.,PMC3582139
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.,PMC4586868
Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses.,PMC4813676
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.,PMC6960448
Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice.,PMC1857191
Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis.,PMC6607999
PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells.,PMC3191120
Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus.,PMC3854932
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.,PMC5921900
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.,PMC3069771
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.,PMC2840093
Immunotherapies: the blockade of inhibitory signals.,PMC3509335
"Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.",PMC4915217
CD21/35 promotes protective immunity to Streptococcus pneumoniae through a complement-independent but CD19-dependent pathway that regulates PD-1 expression.,PMC3717971
Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.,PMC4127946
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2.,PMC2492495
TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance.,PMC4749558
Determinants of Divergent Adaptive Immune Responses after Airway Sensitization with Ligands of Toll-Like Receptor 5 or Toll-Like Receptor 9.,PMC5157987
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.,PMC2778301
Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway.,PMC2941565
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.,PMC4401634
Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1.,PMC2713929
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.,PMC2118162
"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one : National Harbor, MD, USA. 9-13 November 2016",PMC5123387
"33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.",PMC6220480
"34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 : National Harbor, MD, USA. 6-10 November 2019.",PMC6833189
ASGCT 19th Annual Meeting: Abstracts.,PMC5155207
